RAD BioMed

RAD BioMed operates as the investment arm of the RAD Bynet group, strategically allocating capital to early-stage ventures within Israel. The firm's core activity involves providing crucial seed and early-stage funding to promising companies, primarily within the Health, Technology, and Energy sectors. It focuses on identifying high-potential startups and offering comprehensive support to their founding teams as they navigate the initial phases of development and market entry.

The firm was founded in 1992 by Professor Nava Zisapel and Yehuda Zisapel. Drawing upon their extensive experience and established leadership in Israel's high-tech landscape, including Yehuda Zisapel's recognized status as a forefather of the nation's technology industry, they established RAD BioMed. Their insight centered on the critical need to cultivate and financially back emerging enterprises, leveraging their profound understanding of technology innovation and market dynamics to foster local entrepreneurship.

RAD BioMed serves early-stage Israeli startups seeking capital and strategic guidance across its target sectors. The company's vision is to act as a vital catalyst for innovation, identifying and nurturing the next generation of impactful companies. It aims to propel the growth of these ventures, contributing significantly to the advancement of Israel's technology and health ecosystems and supporting their long-term success.